NICE’s prioritisation process explained – what healthtech developers need to know Understand why we're prioritising key topic areas for evaluation and what it means for innovators Rebecca Owens, technical adviser and project specialist - NICE Advice The healthtech sector is transfo...

#NICE #NICEprioritisationprocess #healthtech #NICEevaluation #NICEAdvice #AIpowereddiagnostics #remotemonitoringsolutions #chronicconditions #NICEguidance #NHS #NHScommissioners #NHSInnovationService #NICEguidancedevelopment #NICEappraisal #NHSadoption #NICEguidancepathway
zurl.co/TBJpg

Major changes to type 2 diabetes treatment could save thousands of lives

#NICE #type2diabetes #NICEguidance #NHSsavings #dapagliflozin #NICEfinalguidance #SGLT2inhibitor #flozins #NHScostsavings #SGLT2medicines #clinicallyequivalentgenerics #GLP1receptoragonists #NICEguidelines #healthinequalities #NHSType2DiabetesPathtoRemissionProgramme
zurl.co/0vbyO

NICE backs NHS use of Autolus' leukaemia CAR-T Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

#haematology #NICE #NHS #leukaemiaCART #Autolus #leukaemia #CARTtherapy #NHSroutinecommissioning #Aucatzyl #BcellALL #acutelymphoblasticleukaemia #relapsedALL #refractoryALL #Bcellprecursoracutelymphoblasticleukaemia #ALL #NICEfinaldraftguidance #HTA #FELIXtrial #NICEguidance
zurl.co/h6OwD

"Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market

#menshealth #NICE #prostatecancer #hormonesensitiveprostatecancer #HSPC #abiraterone #JnJ #Zytiga #brandedpharmaceuticals #NICEguidance #advancedHSPC #androgendeprivationtherapy #ADT #Bayer #Nubeqa #Astellas #Xtandi #Erleada #genericmedicines #ProstateCancerUK
zurl.co/fzdbT

NICE finalises support for CSL's HAE therapy Andembry CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE

#NICE #CSL #HAEtherapy #Andembry #garadacimab #PharmaNews #CSLBehring #hereditaryangioedema #HAE #NHS #NICEguidance #NICETAG #FactorXIIainhibitor #HAEpatients #raregeneticdisorder #MHRA #VANGUARDstudy #HAEattacks #HAEUK #AngelaMetcalfe #HAEprevention #EduardoCabas
pharmaphorum.com/news/nice-fi...

New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments

#NHSdiabetesstrategy #GLP1 #NHS #type2diabetes #personalisedapproach #expandedaccess #GLP1agonisttherapies #NHScosts #Individualisedcare #NICEdraftguidance #NICE #SGLT2inhibitors #GLP1receptoragonists #NICEguidance #NHS10Yearplan #patientadvocacy #DiabetesUK
pharmaphorum.com/news/new-nhs...

NICE recommends guselkumab for ulcerative colitis and Crohn’s disease Patients with moderately to severely active ulcerative colitis or Crohn’s disease will now be able to access guselkumab (Tremfya; Janssen Biotech) on the NHS, when other treatments have not worked.…

#NICE guidance recommends guselkumab (#Tremfya; Janssen Biotech) for patients with moderately to severely active ulcerative colitis or Crohn’s disease, when other treatments have not worked

#ulcerativecolitis #crohnsdisease #ukhealthcare #NICEguidance
buff.ly/yQO4cM4

People need support to keep weight off after treatment ends

#NICE #NICEguidance #weightmanagement #weightmanagementsupport #obesity #obesitymedication #weightmanagementprogramme #NICEqualitystandard #NHSBetterHealthplatform #weightlossdrugs #semaglutide #Wegovy #tirzepatide #Mounjaro #NHS #NHS10YearPlan
www.nice.org.uk/news/article...

New cystic fibrosis triple from Vertex backed for NHS use Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

#cysticfibrosis #Vertex #NHSuse #VertexPharma #NHS #England #Wales #CFpatients #Reimbursement #NICE #NICEapproved #NICEguidance #Alyftrek #deutivacaftor #tezacaftor #vanzacaftor #F508delmutation #CFTRgene #cysticfibrosispatients #SKYLINE102 #SKYLINE103
pharmaphorum.com/news/new-cys...

NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

#NICE #EliLilly #Omvoh #Crohnsdisease #BeOneMedicine #Brukinsa #mantlecelllymphoma #ulcerativecolitis #NICEguidance #gastroenterology #SMC #Brukinsa #relapsedMCL #refractoryMCL #Waldenstromsmacroglobulinaemia #chroniclymphocyticleukaemia #marginalzonelymphoma
pharmaphorum.com/news/nice-ba...

NICE recommends sparsentan for IgA nephropathy - PharmaTimes First non-immunosuppressive dual-action therapy approved for eligible patients

#renalmedicine #CSLVifor #nephrology #sparsentan #FILSPARI #IgAnephropathy #nonimmunosuppressivedualactiontherapy #NICE #NHS #primaryIgAnephropathy #PROTECTcliicaltrial #NICEguidance #IgAnephropathypatients #primaryglomerulardisease #kidneyfailure #Proteinuria
pharmatimes.com/news/nice-re...

Overview | Drug-eluting stents for treating coronary artery disease: late-stage assessment | Guidance | NICE

NICE has published new health technology evaluation guidance (HTE26) on drug-eluting stents.
CEDAR was the External Assessment Group behind this work.

Full guidance here: nice.org.uk/guidance/hte26

#NICEGuidance #CardiacStent #CEDARCardiff
@nicecomms.bsky.social

Overview | Drug-eluting stents for treating coronary artery disease: late-stage assessment | Guidance | NICE

Mae NICE wedi cyhoeddi canllawiau gwerthuso technoleg iechyd newydd (HTE26) ar stentiau sy'n rhyddhau meddyginiaeth.

CEDAR oedd y Grŵp Asesu Allanol ar gyfer y gwaith hwn.
Mae’r canllawiau llawn yma: nice.org.uk/guidance/hte26
#NICEGuidance #CEDARCardiff
@nicecomms.bsky.social

Overview | Slide sheets for moving or repositioning a person: late-stage assessment | Guidance | NICE

🆕️ Just published! NICE has released Health Technology Evaluation Guidance on slide sheets for moving or repositioning a person (HTE23).

CEDAR was the External Assessment Group behind this work.

Read the full guidance: nice.org.uk/guidance/hte23

#NICEguidance #SlideSheets #HTA

Up to 1,000 women a year could benefit from new at-home treatment for endometriosis

#womenshealth #endometriosis #symptomsofendometriosis #NICEfinaldraftguidance #NICErecommended #NICEguidance #Linzagolix #Yselty #Theramex #endometriosissymptoms #NHSservices #medicinesevaluation #fasttrackevaluation #patientaccess #NHSinEngland
www.nice.org.uk/news/article...

Why NICE is unlikely to expand recommendations for Cannabis-Based Medicinal Products The National Institute for Health and Care Excellence (NICE) significantly influences which medicines and treatments become available through the NHS. Despite increasing patient advocacy and anecdotal evidence supporting cannabis-based medicinal products (CBMPs), NICE has remained notably cautious. Several key factors contribute to their conservative stance:

Why isn't NICE expanding medical cannabis recommendations? The answer may lie in risk aversion and bureaucracy. This blog breaks down the limitations and future challenges. A must-read for campaigners and clinicians. #CTAUK #CannabisTrades #NICEguidance #MedicalCannabisUK #AccessIssues Read the full

New pill can slow progression of incurable breast cancer Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

#oncology #breastcancer #NHS #capivasertib #Truqap #AstraZeneca #targetedtherapy #AKT #AKTinhibitors #ATKKinases #HRpositivebreastcancer #HER2negativebreastcancer #PIK3CAgene #AKT1gene #PTENgene #NICE #NICEguidance #genetictesting #BreastCancerNow
www.bbc.co.uk/news/article...

9/ Let’s champion high standards without gatekeeping.

Let’s foster innovation without distortion.

And let’s build an NHS ecosystem where the best solutions (plural!) can thrive.

#RealWorldEvidence #DigitalTransformation #HealthTech #NICEGuidance #DigitalHealth #NHSInnovation #HealthPolicy

NICE recommends once-weekly injection for severe blood clotting disorder Final draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended a new treatment for patients aged two years and above with severe haemophilia A. Published on 28…

Draft #NICE guidance has recommended a once-weekly treatment for people aged two years and above with haemophilia A

#haemophilia #blooddisorder #NICEguidance